Mood Disorders

Precision Medicine in Depression: Response to Antidepressants is Associated with the Interplay Between Genetic variants and Gene Expression Levels in Patient-Derived Neurons

We present a study on the interplay between genetic variants and gene expression levels in depressed patients’ neurons and its association with antidepressant response. Neuronal expressio...

Daphna Laifenfeld , PhD;

10/26/2023

Precision Medicine and Target-Controlled Infusions Significantly Improves the Efficacy of Ketamine Therapy for Treatment-Resistant Depression

Precision Medicine and Target-Controlled Infusions (TCI) represent a novel methodology to enhance the effectiveness and durability of ketamine infusion therapy for treatment-resistant dep...

Gerald Grass ;

10/26/2023

Pharmacogenomic Testing in Depression Care: Can Curriculum Based Online Education Improve Provider Knowledge, Competence, and Confidence?

Many clinicians are unaware of the evidence for pharmacogenomic (PGx) testing in depression care and are uncertain as to how to incorporate this modality into clinical decision making. Th...

10/26/2023

Patient Perspectives on Major Depressive Disorder Care to Inform Patient-Centered Approaches

To better understand patients’ experiences and perceptions of their major depressive disorder (MDD) care, we designed a 21-item survey to capture patient perceptions of their MDD symptoms...

Laura Simone , PhD;

10/26/2023

Patient Perspectives of Meaningful Change in Major Depressive Disorder

Findings from qualitative interviews with 19 US adult patients with major depressive disorder (MDD) highlighted the episodic and heterogeneous nature of MDD, as well as the importance of ...

Ankur Doshi , MD;

10/26/2023

Mobile Technology-Supported Shared Decision-Making and Goal Setting for Management of Depression in Primary Care

Mobile-based apps have potential to assist clinicians and patients in the shared decision-making (SDM) process for management of major depressive disorder (MDD). Primary Care Path is a pr...

Christina M. Hester , PhD, MPH;

10/26/2023

Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: Evaluation of Extrapyramidal and Motor Symptoms in Late-Phase Clinical Trials

This analysis evaluated extrapyramidal symptoms (EPS) across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week...

Margaret Martin , PharmD;

10/26/2023

Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder

This randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lumateperone 42mg for the treatment of a major depressive episode in patients with major de...

Suresh Durgam , MD;

10/26/2023

Long-Term Efficacy of Esketamine Nasal Spray Dosed in Accordance With US Prescribing Information in Adults With Treatment-Resistant Depression: A Subgroup Analysis of the SUSTAIN-3 Study Up to 6.5 Years

This subgroup analysis of SUSTAIN-3 (NCT02782104), a phase 3, open-label extension study of esketamine nasal spray (ESK), assessed the long-term efficacy of flexibly dosed ESK in combinat...

Toya Bowles , PharmD, MS, BCPP;

10/26/2023

Long-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression: final results of the SUSTAIN-3 study

In a long-term study (up to 6.6 years) of intermittently-dosed esketamine with daily antidepressant, early improvement in depression was maintained and no new safety signal was identified...

10/26/2023